{"type":"trials","record":{"id":41760,"source_id":"clinicaltrials-gov","external_id":"NCT06198413","title":"LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)","brief_summary":"The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.","overall_status":"Active Not Recruiting","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Innostellar Biotherapeutics Co.,Ltd","enrollment":12,"countries":["China"],"start_date":"2023-02-27","completion_date":"2029-01-01","last_update_date":"2025-07-01","source_url":"https://clinicaltrials.gov/study/NCT06198413","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Innostellar Biotherapeutics Co.,Ltd","interventions":["LX102 subretinal injection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Incidence of dose-limiting toxicity (DLT) — 4 weeks","Incidence of adverse events (AEs) and serious adverse events (SAEs) — 52 weeks","Mean change in BCVA from Baseline — 12 weeks, 36 weeks 52 weeks","Mean change in Central Subfield Thickness (CST) from Baseline — 12 weeks, 36 weeks 52 weeks","Mean time from LX102 administration to anti-VEGF rescue injection for the first time — 52 weeks","Percentage of participants requiring anti-VEGF rescue injection — 52 weeks","Mean number of anti-VEGF rescue injections — 52 weeks"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-Related Macular Degeneration","LX102 subretinal injection"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06198413","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-02-27 to 2029-01-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.867Z","intervention":["LX102 subretinal injection"],"participants":12,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Incidence of dose-limiting toxicity (DLT) — 4 weeks","Incidence of adverse events (AEs) and serious adverse events (SAEs) — 52 weeks","Mean change in BCVA from Baseline — 12 weeks, 36 weeks 52 weeks","Mean change in Central Subfield Thickness (CST) from Baseline — 12 weeks, 36 weeks 52 weeks","Mean time from LX102 administration to anti-VEGF rescue injection for the first time — 52 weeks","Percentage of participants requiring anti-VEGF rescue injection — 52 weeks","Mean number of anti-VEGF rescue injections — 52 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41760","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}